Top 10 Pharmaceutical Stocks to Buy for June 2026: A B2B Analysis

Top 10 Pharmaceutical Stocks to Buy for June 2026: A B2B Analysis

This analysis identifies the top 10 pharmaceutical stocks to buy for June 2026, focusing on catalysts, sales growth, and regulatory tailwinds from the EMA. It provides actionable insights for BD teams, investors, and analysts seeking high-upside opportunities.

Key Takeaways

• Enliven Therapeutics (ELVN) posts a 17.46% 12-week price gain — the strongest momentum signal in the group — though the company has not yet reported projected sales growth, placing it in the binary-risk category typical of early-stage biotechs.
• Collegium Pharmaceutical (COLL) offers a striking 10.68% projected sales growth alongside a 16.74% stock price decline, a divergence that often flags undervaluation or an impending catalyst in pre-commercial or specialty pharma plays.
• Amphastar Pharmaceuticals (AMPH) shows 3.20% projected sales growth with only a modest -2.43% price decline, making it a candidate for bolt-on acquisition screens among mid-cap pharma buyers.
• Biotech names Terns Pharmaceuticals (TERN), ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), and Liquidia Corporation (LQDA) are positioned to outperform in 2026, each carrying distinct regulatory catalysts that BD teams should map against portfolio gaps.
• For income-focused institutional accounts, large-cap pharma stocks Johnson & Johnson (JNJ) and AbbVie (ABBV) remain the core dividend anchors, alongside Merck, Amgen, Gilead, Pfizer, and Zoetis.

What Makes These the Top 10 Pharmaceutical Stocks for June 2026?

The latest Zacks screening for the best pharmaceutical stocks to buy for June 2026 in the USA blends two distinct profiles: high-growth biotechs that offer asymmetric upside tied to pipeline catalysts, and mature large-cap pharma that provide dividend stability. The screening methodology weights recent price momentum alongside one-year-ahead sales growth projections — two metrics that matter when deal teams and portfolio managers decide where to allocate mid-year capital.

Enliven Therapeutics (ELVN) leads the price-momentum category with a 17.46% climb over 12 weeks. That run signals market anticipation around its clinical-stage pipeline, but the absence of projected sales growth figures is a reminder that early-stage biotechs carry binary risk. For every ELVN that delivers a positive readout, there is a counterpart that stagnates. Amphastar Pharmaceuticals (AMPH) offers a contrasting profile: shares slipped 2.43% even as analysts project 3.20% sales growth over the next year. That gap between market sentiment and underlying fundamentals often creates the pricing dislocations that alert BD teams to potential targets. Collegium Pharmaceutical (COLL) widens the divergence further — a 16.74% price drop paired with 10.68% projected sales growth. In specialty pharma, that kind of spread rarely persists without attracting either an activist investor or a strategic buyer who can re-rate the asset under a lower cost of capital.

The biotech cohort singled out by Zacks includes Terns Pharmaceuticals (TERN), ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), and Liquidia Corporation (LQDA). Each of these carries distinct regulatory catalysts. Terns is advancing oral small-molecule candidates in oncology that could trigger re-ratings on clinical data. Liquidia is navigating the FDA and EMA pathways for its inhaled treprostinil product in pulmonary arterial hypertension — a program that has drawn close attention from analysts tracking ClinicalTrials.gov listings. ADMA Biologics operates in the plasma-derived therapy space with approved products that already generate revenue, offering a lower-risk biotech profile. ANI Pharmaceuticals focuses on branded and generic drugs with a pipeline in autoimmune diseases. For business development teams scanning for in-licensing or acquisition candidates, these four names warrant pipeline mapping against therapeutic area priorities — particularly in oncology, rare disease, and immunology.

On the income side, the pharmaceutical stocks list includes the large-cap anchors that institutional accounts rely on for dividend coverage. According to U.S. News, Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Amgen (AMGN), Gilead (GILD), Pfizer (PFE), and Zoetis (ZTS) remain the top picks for investors who need yield stability alongside sector exposure. Each of these names has a diversified revenue base, a clear capital allocation policy for dividends, and pipeline depth that supports long-term total return profiles. For portfolio managers constructing a barbell strategy, these seven stocks serve as the ballast against the volatility that comes with the biotech names.

How Should Pharma Teams and Investors Interpret This List?

For business development executives, the top 10 list functions as a deal-sourcing screen. Collegium and Amphastar both display positive sales growth projections that outpace their recent stock performance — a configuration that historically attracts suitors. A company growing sales at 10.68% while its stock contracts by 16.74% rarely stays independent through a full earnings cycle. The math invites strategic acquirers who can apply their own cost structure and commercial infrastructure to re-rate that growth. Amphastar's 3.20% projected growth paired with a modest price decline positions it as a bolt-on candidate for mid-cap pharma companies looking to add revenue-accretive assets without taking on binary pipeline risk.

For portfolio managers, the distinction between growth biotechs and income large-caps is the central strategic question heading into mid-2026. The best pharma stocks to buy now in the USA require a barbell approach: take calculated positions in the names with the biggest upside potential — Terns and Liquidia, in particular, given their pending regulatory catalysts — while using JNJ and ABBV as core portfolio ballast. The EMA's regulatory calendar will be a critical catalyst for European-exposed names on this list. A positive opinion from the agency on a pipeline asset can drive a step-change in valuation for a small-cap biotech, especially those where the European market represents a significant portion of the addressable patient population.

The top 10 biotech stocks with biggest upside on this list also carry competitive intelligence value. If a large-cap name like Pfizer or Merck makes a move for one of the growth companies here, it signals a therapeutic area priority that could reshape the competitive dynamics in that space. BD teams should map each company's pipeline against their own portfolio gaps — particularly in oncology, rare disease, and immunology — to anticipate where the next round of consolidation may hit. The stocks to buy in June 2026 list is not just an investment tool; it is a strategic preview of where pharma's next wave of value creation will come from.

Analysts tracking this sector should watch for price volatility that creates entry points ahead of those regulatory decisions. The gap between current market pricing and potential catalysts is where alpha lives for managers who can do the fundamental work on pipeline probability and market sizing.

Frequently Asked Questions

Related coverage

• Kairos Pharma Highlights CL-741 Acquisition and 2026 Clinical Milestones: A Strategic Analysis for Pharma Decision-Makers
• Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner
• ASGCT Annual Meeting 2026: Live Event Coverage and Key Insights